[Coagulant activity of factor VII (FVIIc) in the elderly with ischemic heart disease]

R A Fernández de la Puebla Giménez1, P Ceballos, P Pérez Martínez

  • 1Unidad de Lípidos y Arteriosclerosis. Hospital Universitario Reina Sofía. Córdoba.

Medicina Clinica
|January 6, 2001
PubMed

Insights

Coagulant activity of factor VII (FVIIc) may be a significant coronary risk factor in elderly individuals over 75. Higher FVIIc levels were observed in older patients with coronary diseases, suggesting a potential link to cardiovascular risk in this population.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Geriatrics

Context:

  • Coagulant activity of factor VII (FVIIc) is a known risk factor for cardiovascular disease in middle-aged individuals.
  • The role of FVIIc in the elderly population regarding cardiovascular risk remains largely unexplored.
  • This study investigates the potential association between FVIIc levels and coronary heart disease in older adults.

Purpose:

  • To evaluate whether factor VII coagulant activity (FVIIc) serves as a risk factor for coronary heart disease in individuals aged 65-85.
  • To determine if FVIIc levels differ between elderly patients with myocardial infarction/unstable angina and age-matched controls without coronary heart disease.

Summary:

  • A case-control study involving 79 patients (65-85 years) with recent myocardial infarction/unstable angina and 81 controls without coronary heart disease was conducted.
  • No significant difference in FVIIc was found in the total group, but levels were higher in cases over 75 years old (p < 0.05).
  • Multivariable analysis indicated that serum glucose, body mass index, and HDL cholesterol were associated with FVIIc in patients with coronary disease.

Impact:

  • Findings suggest that elevated FVIIc may be a significant coronary risk factor specifically in the very elderly (over 75 years).
  • This research highlights the importance of considering FVIIc in cardiovascular risk assessment for older adult populations.
  • Further investigation into the mechanisms linking FVIIc to cardiovascular disease in the elderly is warranted.
Abstract

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...